Benzene and Acute Myeloid Leukemia: Examining the Causal Link

From General Health Information to Occupational Exposure

The legacy theme of general health and science information has historically provided broad educational content on environmental factors and their potential links to disease. Within this context, discussions often encompassed the properties of common industrial chemicals and their general health implications. Benzene, a widely used solvent in manufacturing, has been a recurring topic in such materials, typically framed within the scope of chemical safety and public health awareness. This foundational knowledge establishes a baseline understanding of benzene as a substance of interest in occupational settings. Transitioning from this general health perspective, the focus narrows to the specific concern of occupational exposure. In mass production environments, benzene is frequently encountered as a component of fuels, solvents, and industrial feedstocks. Workers in sectors such as chemical manufacturing, petroleum refining, and rubber production may face routine contact with this compound. The shift in emphasis moves from broad informational content to the practical realities of workplace exposure, where sustained inhalation or dermal contact becomes a tangible risk. This pivot highlights the need to examine the relationship between such occupational benzene exposure and the development of acute myeloid leukemia, a serious hematologic malignancy, without delving into mechanistic pathways. The transition thus reframes the query from general awareness to a focused occupational health inquiry.

Benzene as a Cause of Acute Myeloid Leukemia: The Evidence

Benzene is a well-established cause of acute myeloid leukemia (AML). Chronic exposure to benzene is recognized as a myelotoxin that increases the risk for hematological neoplasms, including AML, myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279/). The carcinogenic ability of benzene has been reported, and it is acknowledged as a risk element for both solid cancers and hematological malignancies (https://pubmed.ncbi.nlm.nih.gov/34069279/). Clinical presentation of AML typically includes symptoms related to bone marrow failure, such as fatigue, pallor, infection, and bleeding, as well as signs of extramedullary involvement. Diagnosis is confirmed by bone marrow biopsy showing at least 20% blasts, along with cytogenetic and molecular testing to classify subtypes. The disease is aggressive and requires prompt treatment. Benzene is a volatile organic compound used in industrial processes, including as a solvent and in the production of plastics, resins, and synthetic fibers. It is absorbed primarily through inhalation, but also through dermal contact. Benzene is metabolized in the liver to reactive intermediates, such as benzene oxide, which can bind to cellular macromolecules and cause damage. Chronic exposure to benzene at levels of 10 ppm or more has been associated with increased risk of AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). The mode of action for AML development includes multiple early key events, such as hematotoxicity and genetic toxicity in peripheral blood of exposed workers (https://pubmed.ncbi.nlm.nih.gov/33429013/). Prevention of these early events would lead to prevention of the apical adverse outcomes, including morbidity and mortality from myelodysplastic syndromes and AML (https://pubmed.ncbi.nlm.nih.gov/33429013/).

Mechanistic Pathways and Risk Considerations

Several mechanisms have been identified for benzene initiation of hematological tumors, including genotoxic effects, action on oxidative stress and inflammation, and provocation of immunosuppression (https://pubmed.ncbi.nlm.nih.gov/34069279/). However, it is becoming evident that genetic alterations and other causes are insufficient to fully justify several phenomena that influence the onset of hematologic malignancies (https://pubmed.ncbi.nlm.nih.gov/34069279/). Epigenetic effects of benzene in hematologic neoplasms have been reported, including altered gene expression (https://pubmed.ncbi.nlm.nih.gov/34069279/). The key event-informed risk models for benzene-induced AML anticipate that multiple early events, observable in hematotoxicity and genetic toxicity, lead to the development of AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). Given the established causal relationship between occupational benzene exposure and AML (https://pubmed.ncbi.nlm.nih.gov/38727681/), adequate warnings are critical for workers and the public. Occupational exposure limits have been set by regulatory agencies, but the adequacy of warnings regarding benzene and AML may vary. The evidence indicates that benzene exposure is associated with elevated mortality risks for AML, diffuse large B-cell lymphoma, and possibly follicular lymphoma (https://pubmed.ncbi.nlm.nih.gov/38727681/). In a national cohort from Switzerland, occupational exposure to benzene was found to be associated with elevated mortality risks for these cancers (https://pubmed.ncbi.nlm.nih.gov/38727681/). Warnings should emphasize the chronic nature of exposure and the latency period between exposure and disease onset.

Causation and Timeline for Affected Patients

For patients diagnosed with AML who have a history of benzene exposure, causation considerations are important. The evidence shows that benzene exposure increases the risk of AML in children, with an odds ratio of 1.22 (95% CI: 1.02-1.46) per 1 μg/m3 increase in benzene exposure (https://pubmed.ncbi.nlm.nih.gov/41485753/). This finding is based on a meta-analysis of four studies with no heterogeneity (I2 = 0.0%) (https://pubmed.ncbi.nlm.nih.gov/41485753/). For occupational exposure, levels of 10 ppm or more have been associated with increased risk (https://pubmed.ncbi.nlm.nih.gov/33429013/). The timeline between exposure and documented harm can vary, but the mode of action includes early key events that can be observed in hematotoxicity and genetic toxicity (https://pubmed.ncbi.nlm.nih.gov/33429013/). The latency period for benzene-induced AML can range from several years to decades after initial exposure. The key event-informed risk models suggest that early events, such as hematotoxicity and genetic toxicity, occur before the development of AML (https://pubmed.ncbi.nlm.nih.gov/33429013/). These early events can be observed in peripheral blood of exposed workers, providing a potential biomarker for risk assessment (https://pubmed.ncbi.nlm.nih.gov/33429013/). The incorporation of key event information should modify the risk model, but few modification approaches have been suggested (https://pubmed.ncbi.nlm.nih.gov/33429013/). In summary, benzene is a known cause of AML, with evidence from epidemiological studies, mechanistic pathways, and occupational cohort studies. Adequate warnings and risk communication are essential for prevention and early detection.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does benzene cause acute myeloid leukemia?

Yes, benzene is a well-established cause of acute myeloid leukemia (AML). Chronic exposure to benzene is recognized as a myelotoxin that increases the risk for hematological neoplasms, including AML, myelodysplastic syndromes, aplastic anemia, and lymphomas (https://pubmed.ncbi.nlm.nih.gov/34069279/).

What are the early signs of benzene-induced AML?

Early signs of AML include symptoms related to bone marrow failure such as fatigue, pallor, infection, and bleeding. Diagnosis is confirmed by bone marrow biopsy showing at least 20% blasts. Benzene exposure can lead to early key events like hematotoxicity and genetic toxicity observable in peripheral blood (https://pubmed.ncbi.nlm.nih.gov/33429013/).

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Benzene exposure and a confirmed Acute Myeloid Leukemia diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.